What is Senisca?
Senisca operates at the intersection of advanced molecular biology and therapeutic innovation. The company specializes in the development of RNA senotherapeutics designed to target the causative drivers of cellular aging. Unlike conventional treatments that merely manage symptoms, Senisca's platform focuses on the underlying biology of senescence, aiming to restore cellular function and mitigate the progression of age-related pathologies. This scientific rigor has established the firm as a key player in the rejuvenation biotechnology landscape, attracting interest from investors who prioritize deep-science ventures with high clinical impact potential.
How much funding has Senisca raised?
Senisca has raised a total of $7.2M across 2 funding rounds:
Angel/Seed
$2.5M
Other Financing Round
$4.7M
Angel/Seed (2022): $2.5M with participation from R42 Fund, Trend Ventures, Longevity Tech Fund, and Emerging Longevity Ventures
Other Financing Round (2024): $4.7M led by APEX Ventures and R42 Group
Key Investors in Senisca
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies through disruptive technology and strategic guidance.
R42 Group
R42 Group is a venture capital fund and institute that supports deep science ventures from the pre-seed stage to growth, focusing on transformative projects in biotechnology and AI.
Emerging Longevity Ventures
Emerging Longevity Ventures is an investment firm dedicated to the rejuvenation biotechnology sector, providing early-stage capital and strategic support to companies advancing longevity science.
What's next for Senisca?
With the successful closure of this major strategic investment, Senisca is well-positioned to scale its research and development operations. The company is expected to utilize these funds to advance its lead candidates through preclinical validation and potentially initiate early-stage clinical trials. Strategic priorities likely include expanding its intellectual property portfolio, strengthening its internal research capabilities, and fostering partnerships with larger pharmaceutical entities to facilitate the commercialization of its senotherapeutic platform. As the firm matures, its focus will remain on translating complex RNA biology into scalable, life-extending medical solutions that address the global burden of age-related disease.
See full Senisca company page
